Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:PTHN
- CUSIP: N/A
- Web: www.patheon.com/
- Market Cap: $5.07 billion
- Outstanding Shares: 145,136,000
- 50 Day Moving Avg: $34.92
- 200 Day Moving Avg: $31.40
- 52 Week Range: $23.72 - $35.10
Sales & Book Value:
- Trailing P/E Ratio: 44.81
- Foreward P/E Ratio: 23.46
- P/E Growth: 1.57
- Annual Revenue: $1.93 billion
- Price / Sales: 2.63
- Book Value: ($1.95) per share
- Price / Book: -17.92
- EBIDTA: $352.5 million
- Net Margins: 5.71%
- Return on Assets: 4.09%
- Average Volume: 551,683 shs.
- Short Ratio: 2.85
Frequently Asked Questions for Patheon NV (NASDAQ:PTHN)
What is Patheon NV's stock symbol?
Patheon NV trades on the NASDAQ under the ticker symbol "PTHN."
How were Patheon NV's earnings last quarter?
Patheon NV (NASDAQ:PTHN) posted its quarterly earnings results on Thursday, June, 8th. The company reported $0.20 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.19 by $0.01. The company earned $483.40 million during the quarter, compared to the consensus estimate of $466.08 million. The business's revenue for the quarter was up 3.2% compared to the same quarter last year. View Patheon NV's Earnings History.
Where is Patheon NV's stock going? Where will Patheon NV's stock price be in 2017?
7 analysts have issued 12-month target prices for Patheon NV's shares. Their predictions range from $28.00 to $35.00. On average, they anticipate Patheon NV's share price to reach $33.60 in the next year. View Analyst Ratings for Patheon NV.
What are analysts saying about Patheon NV stock?
Here are some recent quotes from research analysts about Patheon NV stock:
- 1. According to Zacks Investment Research, "Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands. " (6/15/2017)
- 2. Jefferies Group LLC analysts commented, "PTHN's results are a further indication of inherent volatility in the CMO business despite long-cycle contracts. FY17 guidance was reduced on FX headwinds and project delays partially offset by the Roche facility acquisition. LT indicators were more positive and we still believe PTHN can generate above industry growth." (3/17/2017)
Who are some of Patheon NV's key competitors?
Some companies that are related to Patheon NV include Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Akorn (AKRX), Taro Pharmaceutical Industries (TARO), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Cambrex Corporation (CBM), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Emergent Biosolutions (EBS), Pacira Pharmaceuticals (PCRX), Innoviva (INVA), Impax Laboratories (IPXL) and Akcea Therapeut (AKCA).
Who are Patheon NV's key executives?
Patheon NV's management team includes the folowing people:
- Paul S. Levy, Chairman of the Board
- James C. Mullen, Chief Executive Officer, Director
- Stuart R. Grant, Chief Financial Officer, Executive Vice President
- Gilles A. Cottier, President - Global Pharmaceutical Development Services
- Franco Negron, President - Drug Product Services
- Lukas Utiger, President - Drug Substance
- Michael J. Lehmann, Executive Vice President - Global Sales and Marketing
- Michael E. Lytton J.D., Executive Vice President - Corporate Development and Strategy
- Rebecca Holland New, Chief Human Resources Officer and Executive Vice President - Communications and Project Management Office
- Harry R. Gill III, Senior Vice President - Quality and Continuous Improvement
When did Patheon NV IPO?
(PTHN) raised $625 million in an initial public offering (IPO) on Thursday, July 21st 2016. The company issued 30,500,000 shares at $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities acted as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers.
Who owns Patheon NV stock?
Patheon NV's stock is owned by a number of of retail and institutional investors. Top institutional investors include
JLL ASSOCIATES G.P. V (PATHEON), LTD.
(43.10%), CNH Partners LLC (0.92%), Glazer Capital LLC (0.78%), Alpine Associates Management Inc. (0.70%), Eagle Asset Management Inc. (0.66%) and Schroder Investment Management Group (0.56%). Company insiders that own Patheon NV stock include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman. View Institutional Ownership Trends for Patheon NV.
Who sold Patheon NV stock? Who is selling Patheon NV stock?
Patheon NV's stock was sold by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Eagle Asset Management Inc., Schroder Investment Management Group, Wells Fargo & Company MN, TIAA CREF Investment Management LLC, New York State Common Retirement Fund, Marshall Wace North America L.P. and Lazard Asset Management LLC. View Insider Buying and Selling for Patheon NV.
Who bought Patheon NV stock? Who is buying Patheon NV stock?
Patheon NV's stock was purchased by a variety of institutional investors in the last quarter, including CNH Partners LLC, Glazer Capital LLC, Alpine Associates Management Inc., Citigroup Inc., Chicago Capital Management LLC, ARP Americas LLC, Commonwealth of Pennsylvania Public School Empls Retrmt SYS and GABELLI & Co INVESTMENT ADVISERS INC.. Company insiders that have bought Patheon NV stock in the last two years include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman. View Insider Buying and Selling for Patheon NV.
How do I buy Patheon NV stock?
Shares of Patheon NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Patheon NV's stock price today?
MarketBeat Community Rating for Patheon NV (NASDAQ PTHN)MarketBeat's community ratings are surveys of what our community members think about Patheon NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Patheon NV stock can currently be purchased for approximately $34.95.
Consensus Ratings for Patheon NV (NASDAQ:PTHN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||6 Hold Ratings, 1 Buy Rating|
|Consensus Rating:||Hold (Score: 2.14)|
|Consensus Price Target: ||$33.60 (3.86% downside)|
Analysts' Ratings History for Patheon NV (NASDAQ:PTHN)
(Data available from 8/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/21/2017||Jefferies Group LLC||Reiterated Rating||Hold||$35.00||Low|
|6/9/2017||Leerink Swann||Downgrade||Outperform -> Market Perform||$31.00 -> $35.00||Low|
|6/9/2017||Raymond James Financial, Inc.||Downgrade||Outperform -> Mkt Perform||Low|
|6/8/2017||J P Morgan Chase & Co||Downgrade||Overweight -> Neutral||Low|
|5/15/2017||William Blair||Downgrade||Outperform -> Market Perform||Low|
|5/15/2017||Piper Jaffray Companies||Downgrade||Overweight -> Neutral||Low|
|3/17/2017||Robert W. Baird||Downgrade||Outperform -> Neutral||$34.00 -> $28.00||Low|
|8/16/2016||Credit Suisse Group||Initiated Coverage||Neutral||$30.00||N/A|
|8/15/2016||Wells Fargo & Company||Initiated Coverage||Outperform||N/A|
|8/15/2016||Morgan Stanley||Initiated Coverage||Overweight||$31.00||N/A|
Earnings History for Patheon NV (NASDAQ:PTHN)Earnings History by Quarter for Patheon NV (NASDAQ PTHN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|6/8/2017||4/30/2017||$0.19||$0.20||$466.08 million||$483.40 million||View||N/A|
|3/16/2017||1/31/2017||$0.22||$0.14||$463.39 million||$457.40 million||View||N/A|
|12/20/2016||Q416||$0.39||$0.30||$496.27 million||$510.20 million||View||N/A|
Earnings Estimates for Patheon NV (NASDAQ:PTHN)
2017 EPS Consensus Estimate: $1.36
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Patheon NV (NASDAQ:PTHN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Patheon NV (NASDAQ:PTHN)Insider Trades by Quarter for Patheon NV (NASDAQ:PTHN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/30/2016||Paul S Levy||Director||Buy||10,000||$29.55||$295,500.00|| |
|9/28/2016||Paul S Levy||Director||Buy||15,000||$29.64||$444,600.00|| |
|9/12/2016||Paul S Levy||Director||Buy||37,000||$28.01||$1,036,370.00|| |
|7/26/2016||Jll Patheon Co-Investment Fund||Major Shareholder||Buy||815,730||$19.85||$16,192,240.50|| |
|7/26/2016||Pamela Daley||Director||Buy||48,800||$19.85||$968,680.00|| |
|7/21/2016||Philip Eykerman||Director||Buy||28,000||$25.00||$700,000.00|| |
Headline Trends for Patheon NV (NASDAQ:PTHN)
Latest Headlines for Patheon NV (NASDAQ:PTHN)
Patheon NV (PTHN) Chart for Thursday, August, 17, 2017